Peapack-Gladstone Financial Corp’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$728K Buy
1,629
+25
+2% +$11.7K 0.01% 434
2025
Q4
$727K Sell
1,604
-7
-0.4% -$3.02K 0.01% 439
2025
Q3
$630K Buy
1,611
+15
+0.9% +$6.27K 0.01% 469
2025
Q2
$711K Sell
1,596
-181
-10% -$83.4K 0.01% 431
2025
Q1
$861K Sell
1,777
-408
-19% -$190K 0.01% 409
2024
Q4
$879K Sell
2,185
-1
-0% -$464 0.01% 402
2024
Q3
$1.02M Buy
2,186
+120
+6% +$57.6K 0.01% 390
2024
Q2
$968K Buy
2,066
+548
+36% +$238K 0.01% 397
2024
Q1
$634K Buy
1,518
+185
+14% +$78.2K 0.01% 452
2023
Q4
$542K Buy
1,333
+130
+11% +$48K 0.01% 473
2023
Q3
$417K Hold
1,203
0.01% 506
2023
Q2
$423K Sell
1,203
-267
-18% -$90K 0.01% 510
2023
Q1
$463K Buy
1,470
+50
+4% +$15K 0.01% 498
2022
Q4
$410K Sell
1,420
-130
-8% -$39.6K 0.01% 492
2022
Q3
$449K Hold
1,550
0.01% 472
2022
Q2
$437K Hold
1,550
0.01% 458
2022
Q1
$402K Buy
1,550
+50
+3% +$11.9K 0.01% 505
2021
Q4
$330K Hold
1,500
0.01% 545
2021
Q3
$272K Buy
+1,500
New +$293K 0.01% 559

Other funds holding VRTX

Peapack-Gladstone Financial Corp's VRTX Position: Q1 2026 in Review

Peapack-Gladstone Financial Corp increased its Vertex Pharmaceuticals (VRTX) stake by 1.6% in Q1 2026, buying an estimated $11.7K and bringing the position to 1,629 shares worth $728K. The position accounts for 0.01% of the portfolio, ranked #434.

Peapack-Gladstone Financial Corp first reported a position in VRTX in Q3 2021 and has held it in 19 quarters since. The position peaked at $1.02M in Q3 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Peapack-Gladstone Financial Corp held 1,629 shares of Vertex Pharmaceuticals worth $728K as of Q1 2026.
  • Peapack-Gladstone Financial Corp bought 25 Vertex Pharmaceuticals shares in Q1 2026, an estimated $11.7K.
  • Vertex Pharmaceuticals made up 0.01% of Peapack-Gladstone Financial Corp's portfolio in Q1 2026, its #434 holding.
  • Peapack-Gladstone Financial Corp first reported a position in Vertex Pharmaceuticals in Q3 2021 and has held it in 19 quarters since.
  • Peapack-Gladstone Financial Corp's Vertex Pharmaceuticals position peaked at $1.02M in Q3 2024.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Peapack-Gladstone Financial Corp's 13F filing for Q1 2026, filed 15 May 2026.